Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus News A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHSubmitted by Nathan Reiff. Published: 2/12/2026. 
Article Highlights - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
Earnings for companies in the healthcare sector are more than a financial check-up — they give investors a window into a firm's pipeline and development progress. Even established healthcare companies can deliver unexpected growth when they launch a blockbuster drug or medical device, and earnings periods give management a chance to provide context and guidance that goes beyond FDA approval announcements. When healthcare companies report on the same day, investors must sort through multiple updates and decide how to position their portfolios. On Feb. 10, 2025, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—each released full-year and Q4 2025 results. Below are the highlights and takeaways for investors. AstraZeneca Strengthens Cancer Business in a Strong Quarterly Performance While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> U.K.-based AstraZeneca finished 2025 reinforcing its position as a leading provider of cancer medicines, which accounted for roughly 44% of product sales in the fourth quarter. Sales of oncology drugs such as Imfinzi and Enhertu grew by as much as 48% year-over-year, helping drive total revenue up 8.6% to $58.7 billion for the quarter. After-tax profits rose alongside revenue, increasing to $10.2 billion from $7 billion in the prior-year quarter. The board approved a second interim dividend that is 7 cents higher than last year's. Investors should also watch AstraZeneca's late-stage pipeline: management said about 20 Phase 3 readouts are expected in 2026. The company reaffirmed expectations for solid gains in both total revenue and core earnings per share (EPS) for full-year 2026. Following the earnings release, AZN shares rose nearly 3% in after-hours trading. While 10 of 11 analysts rate AZN a Buy or equivalent, Wall Street remains cautious on valuation: the consensus price target of $95.75 implies a roughly 51% downside from recent levels. TAVR Momentum Drives Edwards Sales, But Margins and EPS Show Limits Edwards Lifesciences, maker of replacement heart valves and monitoring systems, posted largely positive results for Q4 2025. Sales grew 13.3% year-over-year, powered by strong transcatheter aortic valve replacement (TAVR) demand and uptake of the latest SAPIEN valve iteration. However, adjusted EPS missed analysts' estimates, and gross profit margin declined about 0.8 percentage points year-over-year. Despite the mixed elements, Edwards reiterated its prior 2026 outlook calling for sales growth of 8% to 10% year-over-year and EPS between $2.90 and $3.05. EW shares traded above $80 in after-hours activity, roughly 4% higher than the prior close. Approximately two-thirds of analysts covering EW rate the shares a Buy, and the consensus target implies about 25% upside to $96.77. Orthopedic Demand Supports Zimmer, But Headwinds Persist Zimmer Biomet, which makes joint-replacement systems and implants, saw its shares climb more than 3% in after-hours trading after reporting EPS of $2.42 — four cents above consensus — and revenue of $2.2 billion, up nearly 11% year-over-year and slightly ahead of expectations. Strong demand for orthopedic products helped lift both the top and bottom lines. The company is shifting to focus more on the U.S. market, which accounts for close to 60% of sales. With insured-patient utilization continuing to rise, near-term demand for Zimmer's products may remain robust. Zimmer warned that tariffs could continue to weigh on EPS and revenue in 2026, and management issued conservative guidance in the latest report, projecting adjusted EPS of $8.30 to $8.45 and free cash flow growth of 8% to 10%. Analysts were divided on Zimmer before the release, giving the company an overall Hold rating despite roughly 15% in projected upside based on consensus estimates.
| 
